Scarica l'app Stockscreener
14.06
3.08%
0.42
Dopo l'orario di chiusura:
14.06
Precedente Chiudi:
$13.64
Aprire:
$13.87
Volume 24 ore:
1.16M
Relative Volume:
1.40
Capitalizzazione di mercato:
$851.00M
Reddito:
-
Utile/perdita netta:
$-219.88M
Rapporto P/E:
-3.7757
EPS:
-3.7238
Flusso di cassa netto:
$-175.76M
1 W Prestazione:
+7.08%
1M Prestazione:
-2.09%
6M Prestazione:
+134.72%
1 anno Prestazione:
+69.40%
Intervallo 1D:
$13.79
$14.74
Intervallo di 1 settimana:
$12.40
$14.74
Portata 52W:
$5.68
$16.74
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Nome
Cullinan Therapeutics Inc
Settore
Industria
Telefono
617-410-4650
Indirizzo
ONE MAIN STREET, CAMBRIDGE
Compare CGEM vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
14.06 | 825.58M | 0 | -219.88M | -175.76M | -3.7238 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-17 | Iniziato | Citigroup | Buy |
| 2026-02-02 | Iniziato | Guggenheim | Buy |
| 2025-08-21 | Ripresa | H.C. Wainwright | Buy |
| 2025-06-11 | Ripresa | Stifel | Buy |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-05-01 | Iniziato | Stifel | Buy |
| 2024-04-15 | Iniziato | William Blair | Outperform |
| 2024-02-15 | Iniziato | Wedbush | Outperform |
| 2023-06-15 | Iniziato | TD Cowen | Outperform |
| 2022-11-21 | Iniziato | BTIG Research | Buy |
| 2021-04-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | Iniziato | Evercore ISI | Outperform |
| 2021-02-02 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-02 | Iniziato | SVB Leerink | Outperform |
| 2021-02-01 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Cullinan Therapeutics Inc Borsa (CGEM) Ultime notizie
Clear Street reiterates Cullinan Oncology stock rating on Gilead deal validation - Investing.com
Potential of Cullinan Therapeutics (CGEM) Highlighted by Recent Acquisition - GuruFocus
Swing Trade: Does Cullinan Therapeutics Inc have strong EBITDA marginsMarket Risk Analysis & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Cullinan Therapeutics to lead new discussions on next-generation immune therapies - Traders Union
Decliners Report: What is Cullinan Therapeutics Incs valuation compared to sector2026 PostEarnings & Target Return Focused Picks - baoquankhu1.vn
Rate Cut: Whats the RSI of Cullinan Therapeutics Inc stockMarket Activity Summary & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
CGEM Earnings History & Surprises | EPS & Revenue Results | CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) - ChartMill
Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 data - MarketBeat
Whale Trades: Can Cullinan Therapeutics Inc outperform under higher oil pricesDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Guggenheim Reaffirms Their Buy Rating on Cullinan Management (CGEM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Cullinan Therapeutics (CGEM): Wedbush Raises Price Target to $36 - GuruFocus
Stifel raises Cullinan Oncology stock price target on autoimmune progress By Investing.com - Investing.com Australia
CGEM: Key T-cell engager programs advance toward pivotal milestones and data readouts in 2026 - TradingView
Cullinan Therapeutics: Q4 Earnings InsightsCullinan Therapeutics (NASDAQ:CGEM) - Benzinga
CGEM: 2026 will be pivotal with key data and regulatory milestones for lead T-cell engager programs - TradingView
Cullinan Oncology (CGEM) Projects Strong Cash Position into 2029 - GuruFocus
Cullinan Therapeutics Reports 2025 Financial Results, Updates on CLN-978, Zipalertinib NDA, and 2026 Clinical Milestones - Minichart
Cullinan Therapeutics Inc (CGEM) Reports Q4 Earnings - AlphaStreet
Stifel raises Cullinan Oncology stock price target on autoimmune progress - Investing.com
Cullinan Therapeutics (CGEM) Reports Q4 Loss of $0.77 Per Share, Flat Year-Over-Year - AlphaStreet
Cullinan Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Cullinan Therapeutics 2025 10-K: Advancing First-in-Class Therapies for Autoimmune Diseases and Cancer, Risks, and Strategic Developments - Minichart
Cullinan Therapeutics 2025 Financial Report: Q4 Loss Beats EstimatesNews and Statistics - IndexBox
Cullinan Therapeutics (CGEM) Anticipates Major Developments thro - GuruFocus
Cullinan Therapeutics: Fourth Quarter Earnings Overview - Bitget
Earnings Flash (CGEM) Cullinan Therapeutics Posts Q4 Net Loss $0.77 a Share, vs. FactSet Est of $0.77 Loss - marketscreener.com
Cullinan Therapeutics (NASDAQ:CGEM) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Cullinan Therapeutics 10-K — $0 Revenue, Net Loss $219.9M - TradingView
CGEM: Robust cash reserves and advancing clinical pipeline position for multiple 2026 catalysts - TradingView
Cullinan Therapeutics (Nasdaq: CGEM) details 2025 loss and cash runway into 2029 - Stock Titan
Cullinan Therapeutics: Q4 Earnings Snapshot - WHAS11
Cullinan Therapeutics Q4 net loss widens - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 ... - Bluefield Daily Telegraph
BRIEF-Cullinan Therapeutics Q4 Operating Expenses USD 55.259 Million - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
Jennifer Michaelson Sells 8,000 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics (CGEM) CSO trades options and sells shares - Stock Titan
Cullinan Therapeutics (CGEM) price target increased by 19.75% to 32.84 - MSN
Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen Conference - MarketBeat
Blue Owl Capital Holdings LP Has $14.89 Million Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
What is Cullinan Therapeutics Incs valuation compared to sector2025 Biggest Moves & Precise Buy Zone Tips - baoquankhu1.vn
Can Cullinan Therapeutics Inc generate free cash flowWeekly Stock Recap & Smart Money Movement Tracker - baoquankhu1.vn
Jennifer Michaelson (CGEM) files Form 144: option exercise and 10b5-1 sales - Stock Titan
[SCHEDULE 13G] Cullinan Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
CGEM: Transformational milestones and pivotal data for autoimmune and AML programs expected by 2026 - TradingView
CGEM Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Cullinan Therapeutics (CGEM) Stock Analysis: Exploring A 101% Upside Potential - DirectorsTalk Interviews
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 7.6%Here's Why - MarketBeat
Cullinan Therapeutics Inc Azioni (CGEM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):